Skip to main content

Endometrial Cancer Conference Coverage

Conference Coverage
09/12/2024
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the...
09/12/2024
Oncology
Bradley Corr, MD
Conference Coverage
03/21/2024

Featuring Bradley Corr, MD

Featuring Bradley Corr, MD
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting...
03/21/2024
Oncology
News
03/19/2024
Alex Francoeur, MD, and colleagues investigated the cost-effectiveness of immunotherapy regimes in upfront treatment with chemotherapy for patients with endometrial cancer.
Alex Francoeur, MD, and colleagues investigated the cost-effectiveness of immunotherapy regimes in upfront treatment with chemotherapy for patients with endometrial cancer.
Alex Francoeur, MD, and...
03/19/2024
Journal of Clinical Pathways
Conference Coverage
04/22/2021
JCP Editors
Real-World Tolerability of PARP Inhibitors for Ovarian Cancer in the United States A study presented at the virtual 2021 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer compared the...
Real-World Tolerability of PARP Inhibitors for Ovarian Cancer in the United States A study presented at the virtual 2021 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer compared the...
...
04/22/2021
Journal of Clinical Pathways